A quantitative proteomic approach to evaluate the efficacy of carnosine in a murine model of chronic obstructive pulmonary disease (COPD)

Autor: Alfonsina D’Amato, Alessandra Altomare, Ettore Gilardoni, Giovanna Baron, Marina Carini, Elsa Melloni, Gloria Padoani, Silvia Vailati, Giovanni Caponetti, Giancarlo Aldini

Publikováno v: Redox Biology, Vol 77, Iss , Pp 103374- (2024)

The aim of the work was to study a dose-dependent effect of inhaled carnosine (10, 50 or 100 mg/kg/day) in mice exposed to cigarette smoke as a model of chronic obstructive pulmonary disease (COPD). A dose-dependent loading of the dipeptide in lung t

Externí odkaz: https://doaj.org/article/adda18f45a834203b017be6477eeef7d

In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation

Autor: Laura Cresti, Giovanni Cappello, Silvia Vailati, Elsa Melloni, Jlenia Brunetti, Chiara Falciani, Luisa Bracci, Alessandro Pini

Publikováno v: International Journal of Molecular Sciences, Vol 24, Iss 9, p 7967 (2023)

SET-M33 is a synthetic peptide that is being developed as a new antibiotic against major Gram-negative bacteria. Here we report two in vivo studies to assess the toxicity and efficacy of the peptide in a murine model of pulmonary inflammation. First,

Externí odkaz: https://doaj.org/article/de7859b1a4674dc386b008806f895443

Activity of fosfomycin/colistin combinations against planktonic and biofilm Gram-negative pathogens

Autor: Selene Rebecca Boncompagni, Maria Micieli, Tiziana Di Maggio, Noemi Aiezza, Alberto Antonelli, Tommaso Giani, Gloria Padoani, Silvia Vailati, Lucia Pallecchi, Gian Maria Rossolini

Publikováno v: The Journal of antimicrobial chemotherapy. 77(8)

Objectives To investigate the in vitro activity of fosfomycin, colistin and combinations thereof against planktonic and biofilm cultures of Gram-negative pathogens, mostly showing MDR phenotypes, at concentrations achievable via inhalation of aerosol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1541f9621f2c78d7ac66d0578c68bd3
https://pubmed.ncbi.nlm.nih.gov/35512342

Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo

Autor: Maria Rosaria Carratù, Concetta Altamura, Gloria Padoani, Paola Imbrici, Elsa Melloni, Michela De Bellis, Sabata Pierno, Alessandro Farinato, Jean-François Desaphy, Silvia Vailati, Charlotte Keywood, Diana Conte, Nancy Tarantino, Annamaria De Luca, Carla Caccia

Publikováno v: Experimental neurology. 328

The antiarrhythmic sodium-channel blocker mexiletine is used to treat patients with myotonia. However, around 30% of patients do not benefit from mexiletine due to poor tolerability or suboptimal response. Safinamide is an add-on therapy to levodopa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7cd6d8e3ac70513aeaadd15d2400600
https://pubmed.ncbi.nlm.nih.gov/32205118

Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia

Autor: Elsa Melloni, James Kulisevsky, Clarissa Anna Pisanò, Michele Morari, Fabrizio Gardoni, Gloria Padoani, Carla Caccia, Salvatore Novello, Andrea Brugnoli, Silvia Vailati, Manuela Mellone, Victoria Sosti, Charlotte Keywood

Publikováno v: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy. In addition to its selective and reversible monoamine oxidase B inhibiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc02a2db0fac79c4b675cfa5e65c4499
https://pubmed.ncbi.nlm.nih.gov/30291173